|1.||Reitman, M L: 3 articles (06/2001 - 02/2000)|
|2.||Gavrilova, O: 3 articles (06/2001 - 02/2000)|
|3.||Marcus-Samuels, B: 2 articles (11/2000 - 02/2000)|
|4.||Vinson, C: 2 articles (11/2000 - 02/2000)|
|5.||Cardoso, H: 1 article (01/2013)|
|6.||Martins Ribeiro, L: 1 article (01/2013)|
|7.||Silva Borges, T: 1 article (01/2013)|
|8.||João Oliveira, M: 1 article (01/2013)|
|9.||Martins, S: 1 article (01/2013)|
|10.||IglayReger, H B: 1 article (05/2009)|
04/01/1988 - "In vitro studies of insulin resistance in patients with lipoatrophic diabetes. "
04/15/2001 - "These results suggest that the development of NASH itself may contribute to the insulin resistance observed in lipoatrophic diabetes."
11/18/1999 - "These mice have insulin resistance and other features of lipoatrophic diabetes, and are a faithful model for the human disease. "
01/01/1995 - "Lipoatrophic diabetes (LD) is a syndrome with congenital or delayed onset, characterized by severe insulin resistance and generalized lipoatrophy. "
05/01/1990 - "In vivo and in vitro characterization of insulin resistance in three cases of lipoatrophic diabetes."
|2.||Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy)
06/01/1977 - "This drug improved the general condition of the rabbits with lipoatrophic diabetes, as well as that of the patient with congenital generalized lipodystrophy. "
06/01/1977 - "Lipoatrophic diabetes has been produced in rabbits by injection of a fraction prepared from the urine from patients with congenital generalized lipodystrophy. "
06/01/1977 - "Congenital generalized lipodystrophy and experimental lipoatrophic diabetes in rabbits treated successfully with fenfluramine."
09/01/2002 - "A case of congenital generalized lipodystrophy with lipoatrophic diabetes developing anti-insulin antibodies."
09/01/2000 - "However, with a decrease of fat mass, CLA supplementation resulted in a state resembling lipoatrophic diabetes: ablation of brown adipose tissue, a marked reduction of white adipose tissue, marked hepatomegaly, and marked insulin resistance. "
06/01/2003 - "However, when 1 g CLA/100 g diet was given to mice in a low fat diet (4 g fat/100 g diet), they showed a marked decrease in fat mass, but demonstrated symptoms of lipoatrophic diabetes, i.e., marked hepatomegaly and insulin resistance. "
02/01/2000 - "In lipoatrophic diabetes, a lack of fat is associated with insulin resistance and hyperglycemia. "
01/01/1988 - "Metabolic studies in lipoatrophic diabetes: mechanism of hyperglycemia and evidence of resistance to insulin of lipid metabolism."
01/02/2008 - "The A-ZIP/F-1 transgenic mouse is a model of lipoatrophic diabetes with severe insulin resistance, hyperglycemia and hyperlipidemia. "
01/01/2006 - "It also improves hyperglycemia, insulin resistance, hyperinsulinemia, dyslipidemia and hepatic steatosis in lipoatrophic diabetes. "
11/01/2000 - "The A-ZIP/F-1 phenotype strikingly resembles that of humans with severe lipoatrophic diabetes, including the lack of fat, marked insulin resistance and hyperglycemia, hyperlipidemia, and fatty liver. "
11/01/1972 - "Studies on the pathogenesis of lipoatrophic diabetes: a case of congenital systemic absence of adipose tissue associated with insulin-resistant diabetes mellitus and hepatosplenomegaly."
12/15/1977 - "A 21 years old female patient with lipoatrophic diabetes, a distinct syndrome of insulin resistant diabetes mellitus, loss of subcutaneous fat, hepatosplenomegaly, hyperlipidemia, increased basal metabolic rate, subvalvular aortic stenosis and cystic bone lesions is described. "
|5.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|6.||Extracellular Matrix Proteins
|1.||Fat-Restricted Diet (Diet, Fat Restricted)